Online inquiry

IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3442MR)

This product GTTS-WQ3442MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets HGF gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000601.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3082
UniProt ID P14210
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3442MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7808MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ14157MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ6927MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ4403MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ2265MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ2786MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ15254MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ4590MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW